Fulgent Genetic (FLGT) to Release Quarterly Earnings on Monday

Fulgent Genetic (NASDAQ:FLGT) is scheduled to announce its earnings results after the market closes on Monday, November 6th.

Fulgent Genetic (NASDAQ:FLGT) last announced its earnings results on Monday, August 7th. The company reported $0.02 EPS for the quarter, hitting the consensus estimate of $0.02. The company had revenue of $4.64 million for the quarter, compared to analysts’ expectations of $5.03 million. Fulgent Genetic had a negative return on equity of 0.02% and a negative net margin of 0.42%. On average, analysts expect Fulgent Genetic to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Shares of Fulgent Genetic (NASDAQ FLGT) opened at $3.46 on Friday.

Several research analysts have commented on the stock. Zacks Investment Research upgraded shares of Fulgent Genetic from a “sell” rating to a “hold” rating in a report on Monday, July 10th. Credit Suisse Group lowered their price target on shares of Fulgent Genetic from $11.00 to $10.00 and set an “outperform” rating for the company in a report on Tuesday, August 8th. Piper Jaffray Companies reiterated an “overweight” rating and set a $7.00 price target (down previously from $10.00) on shares of Fulgent Genetic in a report on Wednesday, August 9th. Finally, ValuEngine upgraded shares of Fulgent Genetic from a “sell” rating to a “hold” rating in a report on Monday, October 2nd.

COPYRIGHT VIOLATION NOTICE: This story was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another website, it was illegally copied and reposted in violation of international trademark and copyright legislation. The correct version of this story can be viewed at https://www.com-unik.info/2017/11/04/fulgent-genetic-flgt-to-release-quarterly-earnings-on-monday.html.

In other news, CFO Paul Kim sold 6,134 shares of the company’s stock in a transaction on Friday, August 11th. The shares were sold at an average price of $5.71, for a total value of $35,025.14. Following the completion of the transaction, the chief financial officer now owns 388,602 shares in the company, valued at approximately $2,218,917.42. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders own 58.80% of the company’s stock.

About Fulgent Genetic

Fulgent Genetics, Inc is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes.

What are top analysts saying about Fulgent Genetic? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Fulgent Genetic and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit